Strategy update06/06/2024
QIAGEN announces discontinuation of NeuMoDx systems
QIAGEN N.V. →QIAGEN announced that it would discontinue the NeuMoDx 96 and 288 Molecular Systems, citing post-pandemic market conditions and changing clinical-testing needs. It planned support for existing customers through a transition period into 2025. The decision concerned the product portfolio and does not establish a sale of the acquired company.